Skip to main
DCGO

DocGo (DCGO) Stock Forecast & Price Target

DocGo (DCGO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

DocGo Inc. demonstrates a positive financial outlook, with a reported EBITDA of $830,000 and a 20% margin, indicating strong operational efficiency as the company scales its business. The significant year-over-year growth in patient volumes, including an 113% increase in home visits and a 50% rise in telehealth and lab orders, highlights the demand for its mobile health services and positions the company for continued revenue expansion. Furthermore, the company has raised its revenue and adjusted EBITDA guidance for 2026, reflecting improved performance in its transportation services segment, which is anticipated to contribute to sustained growth and profitability moving forward.

Bears say

DocGo Inc. reported a decline in mobile revenue of 3% year-over-year and 8% quarter-over-quarter for 4Q25, excluding acquisitions and one-time factors. The company faces significant challenges in achieving its adjusted EBITDA guidance, necessitating a reduction of approximately $20 to $22 million in non-GAAP operating expenses amid stagnating organic growth in its core Mobile Health Services segment. Notably, while there was a reported 47% growth in the non-migrant Mobile Health business, the exclusion of SteadyMD's $6.1 million contribution reveals an underlying decline in organic revenue, indicating that the company struggles to scale its fundamental operations effectively.

DocGo (DCGO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DocGo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DocGo (DCGO) Forecast

Analysts have given DocGo (DCGO) a Buy based on their latest research and market trends.

According to 4 analysts, DocGo (DCGO) has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DocGo (DCGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.